Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity
about
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity
description
scientific article published on 18 October 2019
@en
name
Reversible binding of the anti ...... s KXO1's low clinical toxicity
@en
type
label
Reversible binding of the anti ...... s KXO1's low clinical toxicity
@en
prefLabel
Reversible binding of the anti ...... s KXO1's low clinical toxicity
@en
P2093
P356
P1476
Reversible binding of the anti ...... s KXO1's low clinical toxicity
@en
P2093
Jianhong Yang
Lijuan Chen
Yunhua Zheng
P304
18099-18108
P356
10.1074/JBC.RA119.010732
P50
P577
2019-10-18T00:00:00Z